caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1992874473

Kwok Ming LoMD

Hematology-OncologyStamford, CTI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Kwok Ming Lo's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 31 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
STAMFORD HOSPITAL3918,788
HECHT, HARVEY74455
Elizabeth Gaary
Diagnostic Radiology · Hudson, OH
66310
Paul Weinstein
Hematology-Oncology · Stamford, CT
60301
ANGEVINE, ANNE48229
Michael Bar
Hematology-Oncology · Stamford, CT
47295
David Gruen
Diagnostic Radiology · Stamford, CT
46139
Josef Noga
Interventional Radiology · Hudson, OH
41204
Bryan Lazzara
Diagnostic Radiology · Hudson, OH
34199
David Bass
Diagnostic Radiology · Wellington, FL
3080
GALVEZ, MICHELLE26170
Quest Diagnostics Llc
Clinical Laboratory · Wallingford, CT
25128
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
538
Unique beneficiaries
—
Total services
988
Distinct HCPCS
5
Medicare payment
$73K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 119 Hematology-Oncology providers in CT — above median (cohort median 735).
PRESCRIBING · PART D · 2024
Total Rx claims
446
Beneficiaries
—
Total drug cost
$2.1M
Distinct drugs
18
Brand share
40.8%
Top prescribed drugs
Anastrozole111 claims
Abemaciclib41 claims
Acalabrutinib Maleate36 claims
Exemestane27 claims
Zanubrutinib25 claims
QUALITY · MIPS · 2024
Final MIPS score
87.7
Quality
91.2
Cost
65.0
Improvement activities
40.0
Promoting interop.
0.0
Payment adjustment
0.53%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.